pharmaphorum4d
A history of Novartis
Novartis is one of the world's top ... Shared services and Corporate. The company's Pharmaceuticals Division focuses on researching, developing and manufacturing treatments across a variety ...
C&EN1d
Novartis invests in 2 US radiopharmaceutical facilities
Novartis is making two investments in new radiopharmaceutical manufacturing sites in the US. The Swiss pharmaceutical giant will open a third US radioligand plant in Carlsbad, California, to serve the ...
pharmaphorum8d
CMO John Tsai exits, as Novartis starts revamp that aims to save $1bn
With Schaffert's departure, current president of pharma ... spanning corporate and R&D strategy as well as business development, that will be tasked with strengthening Novartis' pipeline in ...
OpenSecrets.org17d
PAC Profile: Novartis Corp
*Based on data released by the Federal Election Commission on September 04, 2024 except for independent expenditure and communication cost, contributions to federal candidates, and contributions from ...
Pharmaceutical Technology on MSN3d
FDA expands Novartis’ Kisqali label to include early breast cancer patients
Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...
JD Supra15d
Novartis Loses Bid for Preliminary Injunction Against MSN Pharmaceuticals
Judge Andrews of the District of Delaware recently denied Novartis’s request for a preliminary injunction against MSN Pharmaceuticals. Novartis Pharm. Corp. v. MSN Pharm. Inc., Civil Action No ...
FiercePharma24d
Novartis taps Lindy to turn biologic drugs into at-home injectables, puts nearly $1B on the line
Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs. For $20 million ...
FiercePharma4d
Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer
An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early breast cancer. The FDA has greenlighted Novartis’ Kisqali, used in ...
Yahoo Finance4d
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali ® (ribociclib) in combination with an aromatase inhibitor (AI ...
Morningstar5d
Kyverna Therapeutics Announces Leadership Update
Previously, Ms. Shaw was an executive at Novartis Pharmaceutical Corporation, including as U.S. country head and President of Novartis Pharmaceutical Corporation and as North American region head ...
Novartis Pharma AG: FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhi ...
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...